An audit of compliance with NICE guidelines for use of rituximab as first line maintenance treatment of follicular non-Hodgkin's lymphoma, in line with East Midlands Guidelines

被引：0
|
作者：
Attwood, C. [1 ]
Boden, A. [1 ]
Fox, C. [1 ]
Richardson, F. [1 ]
McMillan, A. [1 ]
Haynes, A. [1 ]
机构：
[1] Nottingham Univ Hosp NHS Trust, Dept Haematol, Nottingham, England
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2013年 / 161卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
139
引用
收藏
页码：55 / 56
页数：2
相关论文
共 50 条
  • [21] Rituximab maintenance in relapsed or refractory follicular non-Hodgkin's lymphoma: the evidence of its therapeutic value
    Ardeshna, Kirit M.
    CORE EVIDENCE, 2007, 2 (02) : 121 - 129
  • [22] COST OF FIRST LINE TREATMENT OF NON-HODGKIN'S LYMPHOMA AT PRIVATE HOSPITAL EN MEXICO
    Gomez, E.
    Vargas, J.
    Martinez, J.
    Paladio, A.
    VALUE IN HEALTH, 2009, 12 (07) : A379 - A379
  • [23] EECC FOR EVALUATING THE SAFETY OF SUBCUTANEOUS RITUXIMAB IN THE FIRST LINE TREATMENT OF DIFFUSE LARGE CELL B LYMPHOMA OR FOLLICULAR NON HODGKIN LYMPHOMA
    Munoz Ricardo, Garcia
    Blanco Cristina, Quero
    Persona Ernesto, Perez
    Garcia Abel, Domingo
    Lopez Cristina, Perez
    Maria Teresa, Villaescusa de la Rosa
    Ana Margarita, Martinez Castro
    Calvillo Mercedes, Rodriguez
    Tauler Rocio, Sanchez
    Santos Carlos, Panizo
    HAEMATOLOGICA, 2016, 101 : 222 - 223
  • [24] Chlorambucil-rituximab as first-line therapy in patients affected by follicular non-Hodgkin's lymphoma: a retrospective single-centre study
    Martinelli, Giovanni
    Montoro, Juan
    Vanazzi, Anna
    Andreola, Giovanna
    Liptrott, Sarah
    Radice, Davide
    Negri, Mara
    Preda, Lorenzo
    Pruneri, Giancarlo
    Laszlo, Daniele
    HEMATOLOGICAL ONCOLOGY, 2015, 33 (04) : 129 - 135
  • [25] Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma
    Boland, A.
    Bagust, A.
    Hockenhull, J.
    Davis, H.
    Chu, P.
    Dickson, R.
    HEALTH TECHNOLOGY ASSESSMENT, 2009, 13 : 41 - 48
  • [26] RITUXIMAB, MITOXANTRONE, ETOPOSIDE AND CYCLOPHOSPHAMIDE REGIMEN AS FIRST-LINE TREATMENT IN ELDERLY FRAIL PATIENTS WITH AGGRESSIVE NON-HODGKIN'S LYMPHOMA
    Kovalchuk, S.
    Rigacci, L.
    Puccini, B.
    Lancia, F.
    Mannelli, L.
    Benelli, G.
    Bosi, A.
    HAEMATOLOGICA, 2015, 100 : 149 - 149
  • [27] PHASE II STUDY OF FIRST-LINE I-131-RITUXIMAB RADIOIMMUNOTHERAPY OF FOLLICULAR NON-HODGKIN LYMPHOMA: THE INITIAL STUDY
    Macdonald, W.
    McQuillan, A.
    Turner, J. H.
    INTERNAL MEDICINE JOURNAL, 2012, 42 : 16 - 17
  • [28] Bendamustine In Combination With Rituximab As First-Line Treatment For Indolent Non-Hodgkin Lymphoma: Retrospective Analysis Of An Spanish Registry
    Solorzano, Silvia
    Martinez-Chamorro, Carmen
    Panizo, Carlos
    Quero, Cristina
    Deben, Guillermo
    Paz, Jose
    Batile, Ana
    Serrano, Alfons
    Muentes, Zayda
    Gutierrez, Antonio
    Tomas, Jose Francisco
    BLOOD, 2013, 122 (21)
  • [29] Safety of Subcutaneous Administration of Rituximab during the First-Line Treatment of Patients with Non-Hodgkin Lymphoma: The MabRella Study
    Panizo, Carlos
    Bekadja, Mohamed Amine
    Meddeb, Balkis
    Mendoza, Maria Rigoroso
    Truman, Matt
    Smith, Rodney
    Barate, Claudia
    BLOOD, 2016, 128 (22)
  • [30] SAFETY OF SUBCUTANEOUS ADMINISTRATION OF RITUXIMAB DURING THE FIRST-LINE TREATMENT OF PATIENTS WITH NON-HODGKIN LYMPHOMA: THE MABRELLA STUDY
    Panizo, C.
    Bekadja, M. A.
    Meddeb, B.
    Meier, O.
    Smith, R.
    Truman, M.
    Barate, C.
    HAEMATOLOGICA, 2017, 102 : 252 - 253
12345